

Serious Adverse Event Notification	
Update Date	
Country where the AE occurred	
Adverse event notification for	
International case number	
Report number	
ANVISA considerations	
File number	
CE or CEE number	
Num. Clinical protocol	
Study blinding (Who is blinded in this study?)	
Chapter ICD 10	
ICD 10 Group	
ICD 10 category	
ICD 10 sub-category	
Clinical indication	
Severity/Intensity of the disease under study	
Product development phase	
Does the sponsor in Brazil know the allocation of each research subject?	
CPF of the notifier	
Name	
Notifier category	
Specify another category	
Company name	
Contact email (Business)	
Contact email	
Commercial phone)	
Telephone	
Sex	

Serious Adverse Event Notification	
Age	
Date of birth	
Age Range	
Research subject code	
initials	
Allocation	
Description of the intervention procedure	
Type of adverse event notification	
Notification sequence	
Factors and other comorbidities	
Does the volunteer have or have had a concomitant illness or clinical condition?	
ICD10 sub-category (2)	
Start date (2)	
End date (2)	
ICD10 sub-category (3)	
Start date (3)	
End date (3)	
ICD10 sub-category (4)	
Start date (4)	
End date (4)	
ICD10 sub-category (5)	
Start date (5)	
End date (5)	
Institution that maintains the research center	
ORGAN/UNIT	
SERVICE/SUB-UNIT	
Principal investigator's phone number	
Principal investigator	

Serious Adverse Event Notification	
Number of subjects expected in the center	
Number of subjects admitted to the center	
Adverse Event	
MedDRA code	
WHOART for EA	
WHOART term for adverse event	
EA start date	
EA end date	
Narrative	
AE Severity	
Date of knowledge of the adverse event	
Cause of AE in the opinion of the investigator	
Type of adverse event	
CNES number of the service	
Institution that maintains the health service	
ORGAN/UNIT	
SERVICE/SUB-UNIT	
Federation Unit/State	
Postal code of the service location	
Was it supported with resources provided by the sponsor?	
Was any action necessary?	
Action taken	
AIH number (hospital admission authorization)	
Date of interruption of experimental or control treatment	
Another procedure	
Treatment	
Dose	
EA intervention start date	

Serious Adverse Event Notification	
Treatment end date for AE	
Unit in which there was hospitalization	
Postal code of the place of hospitalization	
CNES number of the service	
Date of admission	
Evolution in relation to EA	
Was it necessary to break the masking code?	
Description Medication A	
Dose of Medicine A	
pharmaceutical form	
route of administration	
Manufacturer of Medicine A	
Lot(s) of product A	
Product Category	
Description of Other Product Category	
Start date of use (A)	
End of use date (A)	
Causality WHO (A)	
Did the event occur again?	
Did/does the research subject use other products/medicines?	
Medicine B	
Dose of Medicine B	
pharmaceutical form (B)	
route of administration (B)	
Manufacturer of Medicine B	
Batch of Medicine B	
Product Category	
Description of Other Product Category	

Serious Adverse Event Notification	
Start date of use (B)	
End of use date (B)	
WHO Causality (B)	
Did the event occur again?	
Medicine C	
Dose of Medicine C	
pharmaceutical form (C)	
route of administration (C)	
Product Category	
Description of Other Product Category	
Start date of use (C)	
End of use date (C)	
WHO Causality (C)	
Did the event occur again?	
Medicine D	
Dose of Medicine D	
Product Category	
Description of Other Product Category	
Start date of use (D)	
End of use date (D)	
WHO Causality (D)	
Did the event occur again?	
Medicine E	
Medication Dose (E)	
Product Category	
Description of Other Product Category	
Start date of use (E)	
End of use date (E)	

Serious Adverse Event Notification	
WHO Causality (E)	
Did the event occur again?	
I assume civilly and criminally full responsibility for the data presented	
Notification sending date	